Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Douglas Selinger, PhD (he/him/his)

Plex Research, Massachusetts, United States

As an early pioneer of microarray technology, Douglas authored some of the first publications describing experimental and computational approaches for large scale transcriptional analyses. After completing his Ph.D. in George Church’s lab at Harvard, he joined the Novartis Institutes for Biomedical Research where his 14-year career spanned the entire drug discovery process, including significant work in target ID/validation, high throughput screening, and preclinical safety.

In 2017, Douglas founded Plex Research to develop a novel form of AI based on search engine algorithms. Plex’s unique platform has helped dozens of biotech and pharma companies accelerate their drug discovery pipelines by providing interpretable and actionable analyses of massive chemical biology and omics data sets.

Disclosure information not submitted.

Presentation(s):